Join BIOCYTOGEN at Stanford Drug Discovery Symposium 2025

Join BIOCYTOGEN at Stanford Drug Discovery Symposium 2025

We’re excited to share that Biocytogen will be exhibiting at the Stanford Drug Discovery Symposium 2025! Mark your calendars for April 28–29 in Stanford, CA, where leading biotechnology companies and innovators gather to highlight transformative advancements. This renowned event offers exceptional networking opportunities, bringing together top scientists, investors, and biopharmaceutical leaders to foster collaboration and propel breakthroughs in the life sciences. We can’t wait to connect with you and explore the future of innovation—see you there!

What is Stanford Drug Discovery Symposium 2025?

This event has become a cornerstone in the drug discovery community for networking and collaboration. SDDS 2025 offers a unique opportunity for all members of the drug discovery community – including researchers, pharmaceutical companies, investment groups, academia, and the broader biomedical community – to share ideas and innovations. 

Event Overview  

Date: April 28th – 29th 

Venue: Frances C. Arrillaga Alumni Center, Stanford University

Event Schedule

The Stanford Drug Discovery Symposium 2025 in Stanford, CA will showcase a diverse array of speakers and topics. For a comprehensive look at the daily schedule, including session times and detailed information on each presentation, please refer to the Stanford Drug Discovery Symposium 2025.

About BIOCYTOGEN

Biocytogen is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA(Boston, San Francisco), and Germany (Heidelberg).

We look forward to seeing you at the Stanford Drug Discovery Symposium 2025 in Stanford, CA!

Share:

Back to top
WordPress Double Opt-in by Forge12